|
Remicade (Infliximab; Janssen Biotech Inc., a Johnson&Johnson Company) for treatment of pulmonary sarcoidosis
|
|
|
|
Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Remicade (Infliximab; Janssen Biotech Inc., a Johnson&Johnson Company) for treatment of pulmonary sarcoidosis
. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication Dates. 2011 Authors' conclusions Sarcoidosis is an inflammatory multisystem disorder of unknown etiology that is characterized by the development of noncaseating granulomas (collections of immune cells and other cells) in one or more organ systems. In theory, the disorder is believed to be the result of an immune-mediated response to an unknown antigen. The disease may remit spontaneously with or without treatment, or it may progress to chronic, debilitating disease. Approximately 25% of patients with sarcoidosis have a chronic form of the disease and require long-term therapy to avoid progressive organ dysfunction. The overall mortality rate for sarcoidosis ranges from 1% to 5%; however, for chronic sarcoidosis, the mortality rate is 12%. Sarcoidosis primarily affects the lungs, with more than 90% of patients with the disease presenting with lung involvement. Symptoms of pulmonary sarcoidosis are dyspnea, cough, and retrosternal chest discomfort. The greatest risk associated with pulmonary sarcoidosis is the development of irreversible pulmonary fibrosis, which is the leading cause of sarcoidosis-related death in the United States. While no standardized treatment regimens for pulmonary sarcoidosis have been established, first-line treatment includes high-dose oral or inhaled corticosteroids, although their long-term efficacy for suppressing granulomatous inflammation associated with pulmonary sarcoidosis have not been established. In addition, their cumulative toxicity and relative contraindications render their prolonged use problematic. Hence, there is growing interest in alternative treatment options for sarcoidosis. Indexing Status Subject indexing assigned by CRD MeSH Anti-Inflammatory Agents; Antibodies, Monoclonals; Pulmonary Embolism; Sarcoidosis, Pulmonary Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32012000166 Date abstract record published 28/06/2012 |
|
|
|